Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Aardvark Therapeutics, Inc. (AARD) had Consolidated Net Income/Loss of $-14.39M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-14.39M |
|
-- |
|
-- |
|
$15.08M |
|
$-15.08M |
|
$0.70M |
|
$-14.39M |
|
$-14.39M |
|
$-14.39M |
|
$-14.39M |
|
|
Consolidated Net Income/Loss |
$-14.39M |
$-14.39M |
|
$-15.08M |
|
$-15.09M |
|
21.85M |
|
21.85M |
|
$-0.66 |
|
$-0.66 |
|
| Balance Sheet Financials | |
$80.66M |
|
-- |
|
$0.80M |
|
$81.46M |
|
$6.39M |
|
-- |
|
$0.28M |
|
$6.66M |
|
$74.80M |
|
$74.80M |
|
$74.80M |
|
21.88M |
|
| Cash Flow Statement Financials | |
$-36.47M |
|
$63.00M |
|
$0.27M |
|
$47.05M |
|
$73.85M |
|
$26.80M |
|
$3.95M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.63 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-36.47M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.23% |
|
-19.23% |
|
-17.66% |
|
-19.23% |
|
$3.42 |
|
$-1.67 |
|
$-1.67 |
|